CF PharmTech (HKG:2652) submitted a marketing authorization application for CF017, a budesonide suspension for inhalation, in a Southeast Asian market, according to a Thursday Hong Kong bourse filing.
The drug was approved in China in 2021 and has since been commercialized in the mainland, the filing said.
Shares of the company rose nearly 4% in morning trade Thursday.